0001628280-20-013454.txt : 20200910 0001628280-20-013454.hdr.sgml : 20200910 20200910172438 ACCESSION NUMBER: 0001628280-20-013454 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200908 FILED AS OF DATE: 20200910 DATE AS OF CHANGE: 20200910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CLARK IAN T CENTRAL INDEX KEY: 0001336504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 201169343 MAIL ADDRESS: STREET 1: SOLAZYME, INC. STREET 2: 225 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 wf-form4_159977306538883.xml FORM 4 X0306 4 2020-09-08 0 0001576280 Guardant Health, Inc. GH 0001336504 CLARK IAN T 505 PENOBSCOT DRIVE REDWOOD CITY CA 94063 1 0 0 0 COMMON STOCK 2020-09-08 4 M 0 9146 4.18 A 13789 D COMMON STOCK 2020-09-08 4 S 0 5263 88.6912 D 8526 D COMMON STOCK 2020-09-08 4 S 0 2747 89.7751 D 5779 D COMMON STOCK 2020-09-08 4 S 0 1136 90.5394 D 4643 D STOCK OPTION (RIGHT TO BUY) 4.18 2020-09-08 4 M 0 8070 0 D 2027-05-30 COMMON STOCK 8070.0 10760 D STOCK OPTION (RIGHT TO BUY) 4.18 2020-09-08 4 M 0 1076 0 D 2027-11-29 COMMON STOCK 1076.0 7532 D These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $88.18 to $89.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $89.185 to $90.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $90.22 to $90.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on January 3, 2017. The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on October 25, 2017. /s/ John Saia, as attorney-in-fact for Ian T. Clark 2020-09-10